267P Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)
| Autor: | Sonnenblick, A. 1, Im, S-A. 2, Lee, K.S. 3, Tan, A. 4, Telli, M. 5, Strulov Shachar, S. 6, Bene Tchaleu, F. 7, Cha, E. 8, DuPree, K. 9, Nikanjam, M. 10, Shemesh, C. 11, Xu, J. 12, Zhang, X. 13, Zhu, J. 14, Rugo, H.S. 15 |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S479-S479 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|